Zymeworks(ZYME)
MIDDLETOWN, DEBiotechnology
Focus: Zymeworks is a public biotech company specializing in in silico biologics development, focused on oncology and immunology through antibody-drug conjugates (ADCs) and engineered antibodies. With 501-1,000 employees and a public listing (ZYME), the company operates at mid-cap biotech scale.
Profile data last refreshed 2h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Employees
501-1000
Open Jobs
6+1 this month
Stable — net +1 jobs in 30d
5 added, 4 removed. Backfill posture.
Should You Work at Zymeworks?
AI assessmentZymeworks offers meaningful scientific opportunity in ADC development with recent regulatory validation, but significant financial deterioration and severely limited current hiring create execution risk and entry difficulty.
Why Work Here
- Heavy R&D investment (189% of revenue) signals commitment to pipeline advancement and scientific rigor in a specialized ADC platform
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$76M
Key Products
Futibatinib
Stable
Peak
Most advanced program (Phase 3) with potential for near-term regulatory decision; represents most de-risked asset in pipeline.
Pipeline & Clinical Trials
Help build intelligence for Zymeworks
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.